StreetInsider.com News Articles

Form EFFECT INOVIO PHARMACEUTICALS,

Mon, 13 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759167.html

Form EFFECT INOVIO PHARMACEUTICALS,

Mon, 13 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759167.html

Inovio Pharma (INO) files $300M mixed shelf

Thu, 02 Jul 2026 16:05:55 -0400

Inovio Pharma (NASDAQ: INO) has filed $300,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Inovio Pharma (INO) files $300M mixed shelf

Thu, 02 Jul 2026 16:05:55 -0400

Inovio Pharma (NASDAQ: INO) has filed $300,000,000 mixed shelf of:

Common Stock

Preferred Stock

Debt Securities

Warrants

Form S-3 INOVIO PHARMACEUTICALS,

Thu, 02 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260702/26727450.html

Form S-3 INOVIO PHARMACEUTICALS,

Thu, 02 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260702/26727450.html

Inovio Pharmaceuticals (INO) PT Lowered to $2.50 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:21 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $2.50 (from $3.00) while maintaining a Neutral rating.

The analyst commented: "INOVIO recently reported that its Biologics License Application (BLA) for INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP) is under active review by the FDA, with a PDUFA goal date of October 30, 2026. A mid-cycle review meeting was recently completed. The company is working with the FDA during the review process, including addressing the potential review issue the agency noted in the file acceptance letter regarding

Inovio Pharmaceuticals (INO) PT Lowered to $2.50 at H.C. Wainwright

Mon, 01 Jun 2026 06:55:21 -0400

(Updated - June 1, 2026 6:55 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $2.50 (from $3.00) while maintaining a Neutral rating.

INOVIO to Participate in Upcoming Scientific and Investor Conferences

Thu, 28 May 2026 08:05:00 -0400

PLYMOUTH MEETING, Pa., May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences: